Tag: ASCO

  • Here’s Why Fate Therapeutics Could Run Back to $95

    Here’s Why Fate Therapeutics Could Run Back to $95

    Keep an eye on Fate Therapeutics (FATE). Oversold, the stock is seeing good momentum after highlighting positive interim Phase 1 data from the Company’s FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. “These additional data from our Phase 1 study of FT516…